Lee, S S <br/><br/>
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.  [electronic resource] 

 -  Alimentary pharmacology & therapeutics  Feb 2006 
 - 397-408 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0269-2813 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2036.2006.02748.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiviral Agents--therapeutic use<br/>Canada<br/>Drug Therapy, Combination<br/>Female<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--therapeutic use<br/>Prospective Studies<br/>Recombinant Proteins<br/>Ribavirin--therapeutic use<br/>Treatment Outcome